NLNicole F. Liachko

Nicole F. Liachko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole F. Liachko has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Brian C. Kraemer

    Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA

    13 shared publications
  • Brian C. Kraemer

    University of Washington School of Medicine, Seattle, WA USA

    12 shared publications
  • Thomas D. Bird

    Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA

    9 shared publications
  • Heather N. Currey

    Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA

    7 shared publications
  • Pamela J. McMillan

    Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, USA

    7 shared publications
  • C. Dirk Keene

    Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA

    6 shared publications

Latest Publications

  • Open Access

    Shared and distinct gain-of-function consequences from pathologic cytoplasmic versus nuclear TDP-43

    by Aaron Long, Heather N. Currey, Matvey Goldberg, Randall J. Eck, Marina Han, Rebecca L. Kow, Brian C. Kraemer, Nicole F. Liachko

    While predominantly nuclear localized in healthy cells, TDP-43 can transit between the nucleus and cytoplasm. In frontotemporal lobar degeneration (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), TDP-43 accumulates in hyperphosphorylated cytoplasmic aggregates. However, a subset of patients develops nuclear aggregates. Expression of wild-type TDP-43 in C. elegans neurons results in nuclear protein accumulation and toxic gain of function. To enable comparative study of nuclear and cytoplasmic TDP-43 phenotypes, we generated new models with inactivating mutations in the nuclear localization sequence (NLS) of TDP-43. When compared to nuclear TDP-43 strains, similar protein levels of cytoplasmic TDP-43 cause less neuronal dysfunction in C. elegans . Using RNA sequencing, we determine that transcriptomes are largely unchanged in these models. However, we identify innate immune pathway increases in response to cytoplasmic but not nuclear TDP-43. We find phosphorylation-mediated neurotoxicity of both cytoplasmic and nuclear localized TDP-43 is controlled by the phosphatase calcineurin. We also find that overexpression of the unfolded protein response (UPR) transcription factor XBP-1s worsens outcomes for wild-type TDP-43 animals but improves TDP-43 ΔNLS, suggesting different pathways controlling toxicity and clearance of nuclear versus cytoplasmic TDP-43. Taken together, these data support shared and distinct cellular responses to nuclear versus cytoplasmic TDP-43 localization in an intact animal nervous system. This comparative approach supports a better understanding of human disease and informs therapeutic development for pathological subtypes of TDP-43 proteinopathies.

  • Open Access

    Calcineurin depletion coincides with phosphorylated TDP-43 deposition in a mouse model of ALS/FTLD-TDP

    by Sarah M. Waldherr, Randall J. Eck, Joshua C. Hincks, Heather N. Currey, Matvey Goldberg, Pamela J. McMillan, Aleen D. Saxton, Heino J. Hulsey-Vincent, Caitlin S. Latimer, Brian C. Kraemer, et al.

    Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP) exhibit predominantly cytoplasmic phosphorylated inclusions of the protein TDP-43 as the major neuropathological lesion. Phosphorylated TDP-43 can modify protein aggregation and promote neuronal dysfunction and neurodegeneration in models of ALS and FTLD-TDP. The phosphatase calcineurin has previously been shown to directly dephosphorylate TDP-43 in vitro and prevent accumulation of phosphorylated TDP-43 in vivo in C. elegans . However, it is unknown whether dysregulation of calcineurin contributes to increased TDP-43 phosphorylation and neurodegeneration in the mammalian brain. Here we show in an inducible mouse model of ALS/FTLD-TDP driven by expression and cytoplasmic mislocalization of human TDP-43 (rNLS8 mice), calcineurin protein decreases dramatically in the brain. This depletion coincides with increased levels of the TDP-43 kinase CDC7 and accumulation of phosphorylated TDP-43, and precedes frank neurodegeneration. Using brain-wide single nucleus RNA sequencing (snRNAseq) in symptomatic rNLS8 mice, we find cell-type selective reduced expression of catalytic and regulatory subunits of calcineurin predominantly in GABAergic and glutamatergic neurons. In mouse primary neuron culture and C. elegans models of ALS/FTLD-TDP, we demonstrate activation or overexpression of calcineurin protects against accumulation of phosphorylated TDP-43, neurotoxicity, and neurodegeneration. Taken together, our data suggests calcineurin dysregulation may be a major contributor to loss of brain resilience mechanisms against phosphorylated TDP-43. Restoring calcineurin activity may present a new target for intervening in TDP-43 proteinopathies, including ALS and FTLD-TDP.


  • Open Access

    Decreased Hsp90 activity protects against TDP-43 neurotoxicity in a C. elegans model of amyotrophic lateral sclerosis

    by Laura Garcia-Toscano, Heather N Currey, Joshua C Hincks, Jade G Stair, Nicolas J Lehrbach, Nicole F Liachko

    Neuronal inclusions of hyperphosphorylated TDP-43 are hallmarks of disease for most patients with amyotrophic lateral sclerosis (ALS). Mutations in TARDBP, the gene coding for TDP-43, can cause some cases of familial inherited ALS (fALS), indicating dysfunction of TDP-43 drives disease. Aggregated, phosphorylated TDP-43 may contribute to disease phenotypes; alternatively, TDP-43 aggregation may be a protective cellular response sequestering toxic protein away from the rest of the cell. The heat shock responsive chaperone Hsp90 has been shown to interact with TDP-43 and stabilize its normal conformation; however, it is not known whether this interaction contributes to neurotoxicity in vivo. Using a C. elegans model of fALS mutant TDP-43 proteinopathy, we find that loss of function of HSP-90 protects against TDP-43 neurotoxicity and subsequent neurodegeneration in adult animals. This protection is accompanied by a decrease in both total and phosphorylated TDP-43 protein. We also find that hsp-90 mutation or inhibition upregulates key stress responsive heat shock pathway gene expression, including hsp-70 and hsp-16.1, and we demonstrate that normal levels of hsp-16.1 are required for hsp-90 mutation effects on TDP-43. We also observe that the neuroprotective effect due to HSP-90 dysfunction does not involve direct regulation of proteasome activity in C. elegans. Our data demonstrate for the first time that Hsp90 chaperone activity contributes to adverse outcomes in TDP-43 proteinopathies in vivo using a whole animal model of ALS.


  • Open Access

    Transcriptomic changes preceding neurodegeneration in a C. elegans model of tau and TDP‐43 co‐pathology

    by Vaishnavi Jadhav, Randall Eck, Samuel Smukowski, Laura Garcia Toscano, Caitlin S Latimer, Paul N Valdmanis, Brian C. Kraemer, Nicole F Liachko

    Background: Alzheimer’s disease (AD), the most common aging‐associated neurodegenerative dementia disorder, is defined by the presence of amyloid beta (Aβ) and tau aggregates in the brain. However, more than half of patients also exhibit aggregates of the protein TDP‐43 as a secondary pathology. Clinically, AD patients with secondary TDP‐43 pathology have more severe cognitive impairment, more rapid cognitive decline, worse brain atrophy, and a shorter disease course. TDP‐43 is already implicated in neurodegenerative disease as the major pathological protein aggregate in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD‐TDP), two other devastating neurodegenerative diseases. In patients with mixed Aβ, tau and TDP‐43 pathology, TDP‐43 dysfunction may synergize with neurodegenerative processes in AD, worsening disease. Using C. elegans models of mixed pathology in AD, we have shown that TDP‐43 specifically synergizes with tau but not Aβ, resulting in enhanced neuronal dysfunction, selective neurodegeneration, and increased accumulation of pathological tau.Method: To identify cellular responses to mixed tau and TDP‐43, we have identified distinct transcriptomic signatures from two disease‐relevant timepoints preceding frank neuronal loss in C. elegans.Result: We find that early disease associated changes are driven by tau, but a unique gene expression signature characteristic of co‐morbid tau and TDP‐43 emerges during aging. Using gene ontology and differential splicing analyses, we find significant changes in genes and pathways including lysosomal mediated degradation, lipid metabolism. We have characterized novel modifiers of tau and TDP‐43 identified from their responsive gene expression profiles in tau and TDP‐43 co‐expressing C. elegans.Conclusion: Establishing early cellular responses to co‐morbid tau and TDP‐43 is critical for understanding protective and pathogenic responses to mixed proteinopathies, and an important step in developing therapeutic strategies protecting against pathological tau and TDP‐43 in AD.


  • Open Access

    Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets

    by Vaishnavi S. Jadhav, Jade G. Stair, Randall J. Eck, Samuel N. Smukowski, Heather N. Currey, Laura Garcia Toscano, Joshua C. Hincks, Caitlin S. Latimer, Paul N. Valdmanis, Brian C. Kraemer, et al.


  • Open Access

    Simple models to understand complex disease: 10 years of progress from Caenorhabditis elegans models of amyotrophic lateral sclerosis and frontotemporal lobar degeneration

    by Randall J. Eck, Jade G. Stair, Brian C. Kraemer, Nicole F. Liachko

    The nematode Caenorhabditis elegans are a powerful model system to study human disease, with numerous experimental advantages including significant genetic and cellular homology to vertebrate animals, a short lifespan, and tractable behavioral, molecular biology and imaging assays. Beginning with the identification of SOD1 as a genetic cause of amyotrophic lateral sclerosis (ALS), C. elegans have contributed to a deeper understanding of the mechanistic underpinnings of this devastating neurodegenerative disease. More recently this work has expanded to encompass models of other types of ALS and the related disease frontotemporal lobar degeneration (FTLD-TDP), including those characterized by mutation or accumulation of the proteins TDP-43, C9orf72, FUS, HnRNPA2B1, ALS2, DCTN1, CHCHD10, ELP3, TUBA4A, CAV1, UBQLN2, ATXN3, TIA1, KIF5A, VAPB, GRN, and RAB38. In this review we summarize these models and the progress and insights from the last ten years of using C. elegans to study the neurodegenerative diseases ALS and FTLD-TDP.


  • Open Access

    PATHOGENIC POTENTIAL OF TDP-43 PROTEINOPATHY IN A MICE MODEL OF ALZHEIMER'S DISEASE

    by Laura Garcia Toscano, Joshua Hincks, Pamela Mcmillan, Misa Baum, Nicole Liachko

  • Open Access

    Tau–RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change

    by Pamela J McMillan, Sarah J Benbow, Rikki Uhrich, Aleen Saxton, Misa Baum, Timothy Strovas, Jeanna M Wheeler, Jeremy Baker, Nicole F Liachko, C Dirk Keene, et al.

    Alzheimer’s disease and related disorders feature neurofibrillary tangles and other neuropathological lesions composed of detergent-insoluble tau protein. In recent structural biology studies of tau proteinopathy, aggregated tau forms a distinct set of conformational variants specific to the different types of tauopathy disorders. However, the constituents driving the formation of distinct pathological tau conformations on pathway to tau-mediated neurodegeneration remain unknown. Previous work demonstrated RNA can serve as a driver of tau aggregation, and RNA associates with tau containing lesions, but tools for evaluating tau/RNA interactions remain limited. Here, we employed molecular interaction studies to measure the impact of tau/RNA binding on tau microtubule binding and aggregation. To investigate the importance of tau/RNA complexes (TRCs) in neurodegenerative disease, we raised a monoclonal antibody (TRC35) against aggregated tau/RNA complexes. We showed that native tau binds RNA with high affinity but low specificity, and tau binding to RNA competes with tau-mediated microtubule assembly functions. Tau/RNA interaction in vitro promotes the formation of higher molecular weight tau/RNA complexes, which represent an oligomeric tau species. Coexpression of tau and poly(A)45 RNA transgenes in Caenorhabditis elegans exacerbates tau-related phenotypes including neuronal dysfunction and pathological tau accumulation. TRC35 exhibits specificity for Alzheimer’s disease-derived detergent-insoluble tau relative to soluble recombinant tau. Immunostaining with TRC35 labels a wide variety of pathological tau lesions in animal models of tauopathy, which are reduced in mice lacking the RNA binding protein MSUT2. TRC-positive lesions are evident in many human tauopathies including Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration and Pick’s disease. We also identified ocular pharyngeal muscular dystrophy as a novel tauopathy disorder, where loss of function in the poly(A) RNA binding protein (PABPN1) causes accumulation of pathological tau in tissue from post-mortem human brain. Tau/RNA binding drives tau conformational change and aggregation inhibiting tau-mediated microtubule assembly. Our findings implicate cellular tau/RNA interactions as modulators of both normal tau function and pathological tau toxicity in tauopathy disorders and suggest feasibility for novel therapeutic approaches targeting TRCs.


  • Open Access

    TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans

    by Caitlin S. Latimer, Jade G. Stair, Joshua C. Hincks, Heather N. Currey, Thomas D. Bird, C. Dirk Keene, Brian C. Kraemer, Nicole F. Liachko

    Although amyloid β (Aβ) and tau aggregates define the neuropathology of Alzheimer's disease (AD), TDP-43 has recently emerged as a co-morbid pathology in more than half of patients with AD. Individuals with concomitant Aβ, tau and TDP-43 pathology experience accelerated cognitive decline and worsened brain atrophy, but the molecular mechanisms of TDP-43 neurotoxicity in AD are unknown. Synergistic interactions among Aβ, tau and TDP-43 may be responsible for worsened disease outcomes. To study the biology underlying this process, we have developed new models of protein co-morbidity using the simple animal Caenorhabditis elegans. We demonstrate that TDP-43 specifically enhances tau but not Aβ neurotoxicity, resulting in neuronal dysfunction, pathological tau accumulation and selective neurodegeneration. Furthermore, we find that synergism between tau and TDP-43 is rescued by loss-of-function of the robust tau modifier sut-2. Our results implicate enhanced tau neurotoxicity as the primary driver underlying worsened clinical and neuropathological phenotypes in AD with TDP-43 pathology, and identify cell-type specific sensitivities to co-morbid tau and TDP-43. Determining the relationship between co-morbid TDP-43 and tau is crucial to understand, and ultimately treat, mixed pathology AD.


  • TDP‐43 promotes pathological tau phosphorylation and selective neurotoxicity in C. elegans

    by Caitlin S. Latimer, C. Dirk Keene, Brian C Kraemer, Nicole F Liachko

    Background: TDP‐43‐positive inclusions are present in disease‐affected neurons in over half of patients with Alzheimer’s disease (AD). AD patients with TDP‐43 pathology have worsened clinical outcomes and increased neurodegeneration, but the molecular mechanisms underlying this are unknown.Methods: We have developed new models of multi‐pathology AD by combining tau and TDP‐43 or tau and Aβ in C. elegans neurons. To characterize these transgenic animals, we measured changes in behavioral outcomes, pathological protein accumulation, and neuron loss. We further tested whether the potent tau modifier sut‐2 influences synergistic neurotoxicity exhibited by tau and TDP‐43 co‐expression.Results: TDP‐43 promotes tau but not Aβ neurotoxicity, resulting in enhanced uncoordinated locomotion, neuronal dysfunction, pathological protein accumulation, and selective neurodegeneration through aging. Synergism between tau and TDP‐43 is rescued by sut‐2 loss‐of‐function.Conclusions: Characterizing the relationship between TDP‐43 and tau in vivo is critical to understand and ultimately treat mixed pathology AD. Studies of this novel model of tau and TDP‐43 combined proteotoxicity provide insights into mechanisms underlying tau and TDP‐43 synergistic neurotoxicity. The identification of sut‐2 as a robust modifier of co‐expressed tau and TDP‐43 implicates TDP‐43 as an enhancer of tau toxicity.